aTYR PHARMA INC Repayments of Bank Debt
aTYR PHARMA INC (ATYR) reported Repayments of Bank Debt of $5.20 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfBankDebt · last filed 2017-03-16
- aTYR PHARMA INC repayments of bank debt for the quarter ending 2016-12-31 was $2.65M, a 222.21% increase year-over-year.
- aTYR PHARMA INC repayments of bank debt for the quarter ending 2016-09-30 was $861.00K, a 5.64% increase year-over-year.
- aTYR PHARMA INC repayments of bank debt for the quarter ending 2016-06-30 was $848.00K, a 5.60% increase year-over-year.
- aTYR PHARMA INC repayments of bank debt for the quarter ending 2016-03-31 was $838.00K, a 5.41% increase year-over-year.
- aTYR PHARMA INC repayments of bank debt for fiscal 2016 was $5.20M, a 60.70% increase from fiscal 2015.
- aTYR PHARMA INC repayments of bank debt for fiscal 2015 was $3.24M, a 107.37% increase from fiscal 2014.
- aTYR PHARMA INC repayments of bank debt for fiscal 2014 was $1.56M, a 37.56% decline from fiscal 2013.
- aTYR PHARMA INC repayments of bank debt for fiscal 2013 was $2.50M.
| Period end | Repayments of Bank Debt 3 month | Repayments of Bank Debt 6 month | Repayments of Bank Debt 9 month | Repayments of Bank Debt 12 month |
|---|---|---|---|---|
| 2016-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $3.52M derived: sum of 2 quarters · filed 2017-03-16 | $4.36M derived: sum of 3 quarters · filed 2017-03-16 | $5.20M 10-K · filed 2017-03-16 |
| 2016-09-30 | $861.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $1.71M derived: sum of 2 quarters · filed 2016-11-14 | $2.55M 10-Q · filed 2016-11-14 | $3.37M derived: sum of 4 quarters · filed 2017-03-16 |
| 2016-06-30 | $848.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $1.69M 10-Q · filed 2016-08-10 | $2.51M derived: sum of 3 quarters · filed 2017-03-16 | $3.33M derived: sum of 4 quarters · filed 2017-03-16 |
| 2016-03-31 | $838.00K 10-Q · filed 2016-05-11 | $1.66M derived: sum of 2 quarters · filed 2017-03-16 | $2.48M derived: sum of 3 quarters · filed 2017-03-16 | $3.28M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-12-31 | $824.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $1.64M derived: sum of 2 quarters · filed 2017-03-16 | $2.44M derived: sum of 3 quarters · filed 2017-03-16 | $3.24M 10-K · filed 2017-03-16 |
| 2015-09-30 | $815.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $1.62M derived: sum of 2 quarters · filed 2016-11-14 | $2.41M 10-Q · filed 2016-11-14 | $3.20M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $803.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $1.60M 10-Q · filed 2016-08-10 | $2.38M derived: sum of 3 quarters · filed 2017-03-16 | |
| 2015-03-31 | $795.00K 10-Q · filed 2016-05-11 | $1.58M derived: sum of 2 quarters · filed 2017-03-16 | ||
| 2014-12-31 | $786.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $1.56M 10-K · filed 2017-03-16 | ||
| 2014-09-30 | $775.00K 10-Q · filed 2015-11-10 | |||
| 2013-12-31 | $2.50M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |